Anebulo Pharmaceuticals, Inc. Stock: price and insider trades · United States

Anebulo Pharmaceuticals, Inc. (ANEB) is a U.S.-based clinical-stage biopharmaceutical company that has been listed on NASDAQ in the United States. The company’s strategy is highly focused: it is developing novel solutions for acute cannabis-induced toxic effects, a niche therapeutic area with potential relevance in emergency medicine and pediatrics. Anebulo was founded on April 23, 2020, as a Delaware corporation and has since operated primarily as an R&D-driven biotech rather than a commercial-stage pharmaceutical company. Its headquarters are in Austin, Texas, which gives it access to a growing U.S. life sciences ecosystem and to talent with experience across clinical development, regulatory affairs and capital markets.

Anebulo’s lead program is selonabant. According to recent company disclosures, the oral formulation has completed a Phase 2 clinical trial assessing its ability to block and reverse the negative effects of acute THC intoxication in healthy adults. More recently, management has prioritized the advancement of an intravenous formulation of selonabant, which the company believes could provide a faster development path toward approval, particularly for pediatric patients exposed to cannabis toxicity. That strategic pivot underscores Anebulo’s thesis: rather than building a broad portfolio, it is attempting to establish a first-in-class or best-in-class position around a targeted medical need that remains largely underserved.